
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Click the title above to open the Pharmaceutical Technology April 2018 issue in an interactive PDF format.
over 8 years ago
Modernizing Pharma Manufacturingover 8 years ago
Pharma 4.0over 8 years ago
When One Therapy No Longer Fits Allover 8 years ago
Secondary Packaging Solutions for Injectablesover 8 years ago
Cloud-Connected Platform for Smart Lab Instrumentsover 8 years ago
Additional Certifications for Touchscreen Panelsover 8 years ago
Automated Benchtop Pipetteover 8 years ago
Unlocking the Best Solution for API Sourcing





